BioSpace News Archive

According to the report, the global reprocessed medical devices market was valued at US$ 2.05 Bn in 2020 and is projected to expand at a CAGR of 14.9% from 2021 to 2028.

The global healthcare CRM market is projected to register growth at a CAGR of 14.6% during the forecast period of 2018 to 2023 and gain a valuation of US$ 17.4 Bn by 2023.

According to Transparency Market Research’s latest report on the global osteoporosis drugs market for the historical period 2017–2018 and forecast period 2019–2027, rising prevalence of osteoporosis, growing aging population which is more prone to osteoporosis, and introduction of new therapies are projected to drive the global Osteoporosis Drugs market during the forecast period.

The global mindfulness meditation apps market is expected to register growth at a CAGR of 41.01% during the forecast period of 2020 to 2027 and gain a valuation of US$ 4,206.12 Mn by 2027.

Albany NY, United States: Transparency Market Research has published a new report titled, “Medical Robotic Systems Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”.

Albany NY, United States: According to the report, the global patient engagement solutions market was valued at US$ 17.56 Bn in 2020 and is projected to expand at a CAGR of 15.7% from 2017 to 2028.

Eyenovia, Inc. today announced that the Company will present an ePoster at the American Society of Cataract and Refractive Surgery Annual Meeting, which is being held April 23-26 in Washington, D.C.

Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to GCC19CART, the Company’s lead solid tumor therapy candidate in treating patients with relapsed and refractory metastatic colorectal cancer R/R mCRC.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced safety and pharmacokinetic (PK) data from its Phase 1 study of Niclosamide Inhalation Powder, which is being developed for the treatment of COVID-19.

PDS Biotechnology Corporation announced that on April 18, 2022, the Company received $1.2 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company’s participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss program for State Fiscal Year 2021.